Kornimate/medical-research-clean huggingface dataset:
a dose-escalation pharmacokinetic study of intravenous asa404 in adult advanced cancer patients with impaired renal function and patients with normal renal function

Conditions: Metastatic Cancer

Summary: the purpose of this study is to evaluate the safety and pharmacokinetics of asa404 in patients with refractory or relapsed metastatic cancer with impaired renal function and with normal renal function. it is very possible that patients with renal impairment will show differences in renal excretion of parent asa404 and its metabolites, warranting a study that leads to a better pharmacokinetic assesssment in this population.


Eligibility criteria:
inclusion criteria: * patients having histologically-proven solid tumors, who are either refractory to standard chemotherapy; * patients whom chemotherapy with an investigaional agent in combination with docetaxel, or paclitaxel + carboplatin is appropriate; * creatinine clearance according to cockcroft-gault formula : normal \> 80 ml/min, mild 50-80 ml/min, moderate 30-\<50 ml/min; * a minimum of 4 weeks must have elapsed since the last treatment with other cancer therapies; * potassium, calcium, magnesium and phosphorus values within the normal range; * body mass index (bmi) must be within the range of 18 and 30 exclusion criteria: * patients having cns metastases, must have a ct or mri of the brain performed to rule out cns metastases; * patients with leptomeningeal disease metastases; * radiotherapy \</- weeks prior to starting study drug; * major surgery \</ 4 weeks prior to the start of study; * administration of cyp1a2 and cyp3a4/5 enzyme inducing or inhibiting drugs within 14 days prior to starting study drug; other protocol-defined inclusion/exclusion criteria may apply

Keywords: advanced or metastatic cancer, refractory, core phase, extension phase, dose escalation, standard chemotherapy, doctaxel, paclitaxel, carboplatin, safety, tolerability
a study comparing fascia iliaca blockade vs extracapsular local field infiltration with liposomal bupivacaine

Conditions: Femoro Acetabular Impingement

Summary: the purpose of this study is to compare the effectiveness of fascia iliaca blockade vs local field infiltration with liposomal bupivicaine in controlling pain, narcotic utilization and falls in the postoperative period following hip arthroscopy

the purpose the research is to help determine optimal means of post-operative analgesia following hip arthroscopic procedures. post-operative pain is a significant contributor to patient satisfaction and the side effects of narcotic pain medication are well described. the ideal intervention for achieving appropriate analgesia following hip arthroscopy has not yet been defined. determining means of achieving acceptable post-operative pain relief while minimizing narcotic usage will help yield maximal patient outcomes.the primary research procedures entailed in this study include fascia iliaca nerve blockade with marcaine and local field infiltration with liposomal bupivicane (exparel). the patients in this study will include those who have both a clinical and radiographic diagnosis of femoracetabular impingement (fai), have failed non operative treatment, and are indicated for hip arthroscopy with labral repair and femoroplasty/acetabuloplasty. the study includes the surgical procedure and the first post-operative follow up visit. the total study duration is approximately 1.5 weeks for each patient. the study will be carried out until the patients first post-operative visit which typically occurs 7-10 days after the procedure. we are to include approximately 40 patients in total for this study over a period of 4 months.

Eligibility criteria:
inclusion criteria: * adult patients (\>18 years old) * diagnosed fai that are indicated for hip arthroscopic labral repair and femoroplasty/acetabuloplasty. exclusion criteria: * patients undergoing revision procedures, bilateral procedures, * advanced osteoarthritis (\<2mm joint space on plain radiographs) * frank dysplasia (anterior and/or lateral center edge angles \ 15 degrees) * diagnoses other than fai (legg calve perthes, femoral head avascular necrosis, septic arthritis, or post traumatic deformity). * allergy to liposomal bupivicaine

Keywords: hip arthroscopy
a prospective, descriptive cohort study with prontosan® wound gel x in partial and full thickness burns requiring split thickness skin grafts

Conditions: Burns

Summary: the purpose of this study is to evaluate the healing of split thickness skin grafts when treated with prontosan® wound gel x in patients with partial and full thickness skin burns.


Eligibility criteria:
inclusion criteria: * partial of full thickness burns requiring split thickness grafts * target burn wound size 10cm2-1000cm2 * age ≥ 18 years * ability to read, write and speak german. * provision of voluntary consent to participate in the study, following a full explanation of the nature and purpose of the study, by signing the informed consent approved by the institutional ethics committee (iec) prior to all evaluations. informed consent will be obtained from the patient or by a legal representative if the patient is not able/competent to consent. in this case, informed consent will be also obtained by the patient when he/she regains competence. * women of child bearing potential must test negative on standard urine pregnancy test and must agree to practice appropriate contraceptive methods for the duration of the study (e. g. oral contraceptive, iud, intra-muscular contraceptive, abstinence). exclusion criteria: * target wound has exposed hyaline cartilage * connective tissue disorder * previous skin graft failure at target wound site * total burn surface area ≥ 70% * infected target wound * immunosuppression therapy * chronic hemodialysis * steroid use * diabetes (type i) * allergy or sensitivity to any of the ingredients in prontosan® wound gel x * allergy or sensitivity to chlorhexidine * pregnancy * simultaneous participation in another clinical trial

Keywords: polyhexanide, polihexanide, phmb, prontosan, burns, wounds
testing video information about mammography screening

Conditions: Breast Cancer

Summary: this study examines how video information about mammography screening effect participants knowledge opinions and choice about screening.

this study will be conducted as a single site parallel-arm, 1:1 randomized controlled trial (rct) through a web-based quantitative survey uploaded in online forums. participants will be randomized to either the intervention group (video information about mammography screening followed by a survey about mammography screening) or the control group (video information about energy systems followed by the same survey). the survey computer programme will randomly assign each respondent to either the intervention arm or the control arm in the beginning of the survey. the allocation will be concealed from the researchers. the survey computer programme will deliver the intervention right after randomization. participants will be aware of the allocation. however, they do not know about the study design. data analysts will be kept blinded to the allocation. choice, knowledge and opinions related to mammography screening will be compared between the control group and the intervention group at one timepoint.

Eligibility criteria:
inclusion criteria: * participants eligible for the study includes all men and women age 18-75. exclusion criteria: * none
immunonutrition and psychosocial factors in the recovery of patients after gastrectomy: a multidimensional analysis

Conditions: Gastric Cancer; Salutogenesis; Sense of Coherence

Summary: to conduct this research, the following guiding question was formulated: "can immunonutrition, combined with the assessment of soc and resilience, provide a broad view of the physical and psychological results during the treatment and recovery process of patients undergoing gastric cancer surgery?". this led to the formulation of the following hypothesis: "patients who received immunonutrition and who have higher levels of resilience and sense of coherence will tend to exhibit more favorable clinical and laboratory outcomes for recovery after gastric cancer surgery. in order to answer the question and test the study hypothesis, the general objective consisted of: to evaluate the association of clinical and laboratory outcomes with the sense of coherence and resilience of patients undergoing gastric cancer surgery who received immunonutrition. in view of this general objective, the following specific objectives were formulated: * to evaluate the levels of resilience and sense of coherence in patients undergoing gastric cancer surgery who received immunonutrition. * analyze the results of blood count and c-reactive protein (crp) in patients who received immunonutrition after gastric cancer surgery. * identify the association between resilience levels, sense of coherence, blood count and crp values with clinical outcomes, such as length of hospital stay and wound recovery, in patients undergoing gastric cancer surgery who used immunonutrition.


Eligibility criteria:
inclusion criteria: adult or elderly patients (age ≥ 18 years) treated at consultório guararapes underwent surgery to remove gastric cancer used immunonutrition in the pre, post, or perioperative period applicable to both sexes exclusion criteria: pre-existing hematologic diseases that may affect blood count results history of drug abuse (legal and/or illegal) presence of other neoplasms history of psychological disorders affecting ability to respond to study questionnaires
the use of a new safe angle position for implant placement in the anterior region.

Conditions: Immediate Implant Placement; Esthetic Zone; Anterior Maxilla; Safe Angle Position

Summary: there is an angle between the intersection of the incisal long axis perpendicular to the palate or the occlusal plane, and the long axis of the root. when this relation is shifted more palatal, where the incisal plane line will be at the cingulum position or slightly palatal to it, it is named the safe angle position. the more palatal relocation to the cingulum is performed according to the availability of palatal bone, the occlusion with the opposing dentition, the type of the restoration (screw vs cemented). the possibility of having a specific safe angle to place implants opens new interesting perspectives for immediate placement of dental implants. the aim of the present study was to demonstrate how immediate implants in the safe angle position can be predictably achieve proper implant positioning, better esthetics and emergence profile as well as less stresses on the implant.

immediate implants are implants inserted immediately after surgical extraction of the teeth to be replaced. creation of an anatomically correct emergence profile is one of the most important aspects in providing an esthetically pleasing implant-supported restoration. dentists understand the risks involved when restored prostheses are subjected to non-axial loading. it has always been recommended to direct occlusal loads as close to the long axis of the fixture as possible. however, it is known that the loading on angled abutments is mostly off-axis, which raises the concern of how angled abutments generally perform with such an unfavourable loading regimen. there is an angle between the intersection of the incisal long axis perpendicular to the palate or the occlusal plane, and the long axis of the root. when this relation is shifted more palatal, where the incisal plane line will be at the cingulum position or slightly palatal to it, it is named the safe angle position. the more palatal relocation to the cingulum is performed according to the availability of palatal bone, the occlusion with the opposing dentition, the type of the restoration (screw vs cemented). the possibility of having a specific safe angle to place implants opens new interesting perspectives for immediate placement of dental implants. the aim of the present study was to demonstrate how immediate implants in the safe angle position can be predictably achieve proper implant positioning, better esthetics and emergence profile as well as less stresses on the implant.

Eligibility criteria:
inclusion criteria: 1. patients with immediate implants in the anterior region 2. patient with preoperative and postoperative cbct 3. provide informed consent. exclusion criteria: 1. patients without a preoperative cbct. 2. 2- patients without an informed consent.

Keywords: immediate dental implants anterior maxilla safe angle position
acute assessment of a micro multipolar lead for enhanced cardiac resynchronisation therapy

Conditions: Cardiac Resynchronisation Therapy

Summary: pilot study to evaluate the performance of a lead below 2 french with specific distal shape to deliver efficient lv pacing


Eligibility criteria:
inclusion criteria: * male or female patient aged ≥18 years old. * patient presenting a crt-p or crt-d indication according to the latest esc guidelines . * primary implant of a crt device (including upgrade from a single or dual-chamber pacemaker or icd). * signed and dated informed consent. * patient affiliated with, or beneficiary of a social security category. exclusion criteria: * class iv of nyha (ambulatory or not). * allergy to contrast media used for imaging during cardiac catheterization. * severe renal failure (clearance of creatinine \< 30ml/mn/m²). * previous failure catheterization of the coronary sinus, or previous failure of left ventricular lead implantation. * already included in another clinical study involving intra-cardiac active implantable device, or participation to any other clinical trial in the last 2 weeks. * person deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision). * known pregnancy, breastfeeding women or in childbearing age without an adequate contraceptive method (failure rate \< 1%).

Keywords: quadripolar lv leads
evaluation of epalrestat in metastatic triple-negative breast cancer

Conditions: Triple Negative Breast Cancer

Summary: to evaluate the efficacy and safety of epalrestat in the treatment of metastatic triple negative breast

this is a phase ii,single center,prospective, single arm clinical trials. the objective is to evaluate the efficacy and safetyof epalrestat in the treatment of metastatic triple negative breast.primary endpoint is 16-week clinical benefit rate (cbr).

Eligibility criteria:
inclusion criteria: * female ≥ 18 years, ≤70 years. * minimum life expectancy 16 weeks * histologicalconfirmation of hormone receptor negative and her2 negative breast cancer(ihc:er -, pr-) on primary tumour at diagnosis/on biopsy of metastasis * clinical or histological confirmation of metastatic or locally advanced disease not amenable to curative surgical resection * ecog 0-2 with no deterioration over previous 2 weeks measurable disease * adequate bone marrow and organ function * availability of archival tumour sample or fresh biopsy informed consent * normal organ function exclusion criteria: * last dose chemotherapy, immunotherapy targeted therapy, biological therapy or tumour embolisation \<21 days prior to study treatment * last dose of palliative radiotherapy \<7 days prior to study treatment * rapidly progressive visceral disease not suitable for further therapy * spinal cord compression or brain/meningeal metastases unless asymptomatic, treated and stable and not requiring steroids for ≥ 4 weeks study treatment * major surgery (excluding placement of vascular access) within 4 weeks before study treatment * evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis b, hepatitis c and hiv * with the exception of alopecia, any unresolved toxicities from previous therapy greater than ctcae grade 1 before study treatment * elevated alp in absence of bone metastasis * evidence of dementia, altered mental status or any psychiatric condition that would prohibit understanding or rendering of informed consent * participation in another study with investigational product during last 30 days * inability or unwillingness to comply with study procedures, including inability to take regular oral medication

Keywords: triple negative breast cancer epalrestat
lesion dosimetry with iodine-124 in metastatic thyroid carcinoma

Conditions: Thyroid Carcinoma; Metastatic Thyroid Carcinoma

Summary: the purpose of this study is to evaluate a new diagnostic imaging test, positron emission tomography (pet), with a different radioactive form of iodine called iodine-124. this form is able to accurately measure the amount of radioactive iodine uptake in the cancer. if the new test determines sufficient radioiodine uptake in the cancer, treatment will continue as usual. however, if the new test shows only low radioiodine uptake, a decision may be made that the benefit from radioiodine therapy is insufficient and that another form of therapy is preferred.


Eligibility criteria:
inclusion criteria: * adults with thyroid carcinoma confirmed by pathology. * adult thyroid carcinoma patients who have undergone total thyroidectomy * adult thyroid carcinoma patients have metastatic disease or suspicion for metastatic disease, or are under a protocol intended to explore re-induction therapy for 131i uptake, and are about to undergo thyrogen-assisted dosimetry, unless thyrogen-assisted dosimetry is not required per standard of care. * the patient and physician are planning to administer 131i for therapy if persistent radioiodine-avid metastases are present. * all subjects must have measurable disease, documented within the previous six months by ultrasonography (us), mri, fdg pet/ct, or ct scanning. exclusion criteria: * age less than 18 years. * patients who are pregnant.

Keywords: iodine-124 pet scan 18-253
the prevalence of fibromyalgia in adults at al-karak jordan a cross-sectional study

Conditions: Fibromyalgia; Orthopedic Disorder

Summary: fibromyalgia is a chronic and intricate musculoskeletal disorder characterized by widespread pain, fatigue, and tenderness in specific anatomical regions. although its prevalence varies among populations, understanding the prevalence in different geographical areas is crucial for healthcare planning. this cross-sectional study aims to determine the prevalence of fibromyalgia in adults residing in al-karak, jordan. the city's unique demographic and environmental characteristics may influence the occurrence of fibromyalgia among its adult population. the study aims to address gaps in knowledge, provide localized insights, and shed light on fibromyalgia's burden on the community's health. accurate prevalence data aids healthcare planning and resource allocation.


Eligibility criteria:
using google forms, this cross-sectional study was carried out, and the participants were reached via social media platforms (5) . participants' autonomy was maintained, and no direct benefit was gained in return for filling out the questionnaire. the ethics committee at the faculty of medicine, mutah university, karak, jordan, provided the required ethical approval prior to the initiation of this study. moreover, the committee ensured that the study was designed according to the principles of the declaration of helsinki (date: 13 february 2023. reference number: 992023). in this study, the authors targeted karak government citizens, in jordan. accordingly, the required sample size to achieve a 99% confidence interval was 663 participants.
comparisons of iv ibuprofen and iv paracetamol during bariatric surgery

Conditions: Bariatric Surgery Candidate; Obesity, Morbid

Summary: the aim of this study is to evaluate and to compare the effectiveness of iv ibuprofen and iv paracetamol during bariatric surgery.

evaluation of effectiveness of iv ibuprofen and iv paracetamol on postoperative pain, opioid consumption, and side effects in morbidly obese patients undergoing bariatric laparoscopic surgery

Eligibility criteria:
inclusion criteria: * patients undergoing laparoscopic sleeve gastrectomy and gastric by-pass surgery exclusion criteria: * hepatic disfunction, * renal failure (creatinine \> 3 mg/dl,creatinin clearance \< 60 ml/dk or urine out-put \< 500 ml/day ) or a history of dialysis 28 days before surgery, * a history of gastrointestinal bleeding or bleeding diathesis 6 weeks before surgery, therapeutic dose of anticoagulation therapy (except subcutaneous heparin prophylactic dose), * angiotensin converting enzymes inhibitor or antihypertensive combination with furosemide, * a history of opioid addiction or opioid tolerance * allergy to study drugs, * noncooperative patients for pain assessments

Keywords: bariatric surgery morbid obesity nonopioid analgesics
a study of peresolimab (ly3462817) in participants with moderately-to-severely active rheumatoid arthritis

Conditions: Rheumatoid Arthritis; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Summary: the main purpose of this study is to assess the safety and efficacy of peresolimab in adult participants with moderately-to-severely active rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * have a diagnosis of adult onset rheumatoid arthritis (ra) for at least 3 months prior to screening, as defined by the 2010 acr/european league against rheumatism (eular) classification criteria * have moderately-to-severely active ra, at screening and baseline, defined by the presence of * ≥6 swollen joints based on 66 joint count, and * ≥6 tender joints based on 68 joint count. * have had an inadequate response to, or loss of response or intolerance to at least 1 conventional synthetic dmard (csdmard), biologic dmard ( bdmard), or targeted synthetic dmard (tsdmard) treatment. exclusion criteria: * have class iv ra according to acr revised criteria. * have presence of 1 or more significant concurrent medical conditions per investigator judgment, including but not limited to * poorly controlled diabetes or hypertension * chronic kidney disease stage iiib, iv, or v * symptomatic heart failure according to new york heart association class ii, iii, or iv * myocardial infarction, unstable angina pectoris, stroke or transient ischemic attack, within the past 12 months before randomization * severe chronic pulmonary disease, for example, requiring oxygen therapy * major chronic inflammatory disease or connective tissue disease other than ra, including but not limited to, * systemic lupus erythematosus * psoriatic arthritis * axial spondyloarthritis including ankylosing spondylitis and non-radiographic axial spondyloarthritis * reactive arthritis * gout * scleroderma * polymyositis * dermatomyositis * active fibromyalgia, or * multiple sclerosis